127 related articles for article (PubMed ID: 27046339)
1. Combination Therapy With Coenzyme Q10 and Trimetazidine in Patients With Acute Viral Myocarditis.
Shao L; Ma A; Figtree G; Zhang P
J Cardiovasc Pharmacol; 2016 Aug; 68(2):150-4. PubMed ID: 27046339
[TBL] [Abstract][Full Text] [Related]
2. Combination of trimetazidine and coenzyme Q10 for the treatment of acute viral myocarditis: a systematic review and meta-analysis.
Zeng M; Chen Z; Zhang Y; Pang Y
J Infect Dev Ctries; 2024 May; 18(5):658-665. PubMed ID: 38865387
[TBL] [Abstract][Full Text] [Related]
3. Treatment of acute inflammatory cardiomyopathy with intravenous immunoglobulin ameliorates left ventricular function associated with suppression of inflammatory cytokines and decreased oxidative stress.
Kishimoto C; Shioji K; Kinoshita M; Iwase T; Tamaki S; Fujii M; Murashige A; Maruhashi H; Takeda S; Nonogi H; Hashimoto T
Int J Cardiol; 2003 Oct; 91(2-3):173-8. PubMed ID: 14559127
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Trimetazidine in Limiting Periprocedural Myocardial Injury in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis.
Wang C; Chen W; Yu M; Yang P
Angiology; 2021 Jul; 72(6):511-523. PubMed ID: 33472383
[TBL] [Abstract][Full Text] [Related]
5. Effects of Coenzyme Q10 Supplementation on Gene Expressions Related to Insulin, Lipid, and Inflammation Pathways in Patients With Diabetic Nephropathy.
Heidari A; Hamidi G; Soleimani A; Aghadavod E; Asemi Z
Iran J Kidney Dis; 2018 Jan; 12(1):14-21. PubMed ID: 29421772
[TBL] [Abstract][Full Text] [Related]
6. Anti-oxidant effects of coenzyme Q10 on experimental viral myocarditis in mice.
Kishimoto C; Tomioka N; Nakayama Y; Miyamoto M
J Cardiovasc Pharmacol; 2003 Nov; 42(5):588-92. PubMed ID: 14576505
[TBL] [Abstract][Full Text] [Related]
7. The effect of coenzyme Q10 plus trimetazidine on acute viral myocarditis treatment.
Yin YJ; Zeng SL; Li YW; Wu Z; Huang DJ; Tang HZ
Am J Transl Res; 2021; 13(12):13854-13861. PubMed ID: 35035725
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome of patients with virus-negative chronic myocarditis or inflammatory cardiomyopathy after immunosuppressive therapy.
Escher F; Kühl U; Lassner D; Poller W; Westermann D; Pieske B; Tschöpe C; Schultheiss HP
Clin Res Cardiol; 2016 Dec; 105(12):1011-1020. PubMed ID: 27312326
[TBL] [Abstract][Full Text] [Related]
9. Trimetazidine attenuates high-altitude fatigue and cardiorespiratory fitness impairment: A randomized double-blinded placebo-controlled clinical trial.
Yang J; Zhang L; Liu C; Zhang J; Yu S; Yu J; Bian S; Yu S; Zhang C; Huang L
Biomed Pharmacother; 2019 Aug; 116():109003. PubMed ID: 31125823
[TBL] [Abstract][Full Text] [Related]
10. [Clinical and hemodynamic efficacy of selective beta-blocker bisoprolol and cytoprotector trimetazidine in the treatment of chronic cardiac failure in patients with ischemic heart disease].
Fedorova TA; Il'ina IuV; Sotnikova TI; Rybakova MK; Loshchits NV
Ter Arkh; 2004; 76(3):62-8. PubMed ID: 15108463
[TBL] [Abstract][Full Text] [Related]
11. Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d'Abruzzo Trimetazidine Trial.
Di Napoli P; Di Giovanni P; Gaeta MA; Taccardi AA; Barsotti A
J Cardiovasc Pharmacol; 2007 Nov; 50(5):585-9. PubMed ID: 18030070
[TBL] [Abstract][Full Text] [Related]
12. Correlations of the changes in bioptic findings with echocardiographic, clinical and laboratory parameters in patients with inflammatory cardiomyopathy.
Krejci J; Hude P; Poloczkova H; Zampachova V; Stepanova R; Freiberger T; Nemcova E; Spinarova L
Heart Vessels; 2016 Mar; 31(3):416-26. PubMed ID: 25539624
[TBL] [Abstract][Full Text] [Related]
13. Trimetazidine and the contractile response of dysfunctional myocardium in ischaemic cardiomyopathy.
Belardinelli R
Rev Port Cardiol; 2000 Nov; 19 Suppl 5():V35-9. PubMed ID: 11206102
[TBL] [Abstract][Full Text] [Related]
14. Role of trimetazidine in management of ischemic cardiomyopathy.
Bertomeu-Gonzalez V; Bouzas-Mosquera A; Kaski JC
Am J Cardiol; 2006 Sep; 98(5A):19J-24J. PubMed ID: 16931202
[TBL] [Abstract][Full Text] [Related]
15. Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy.
Belardinelli R; Cianci G; Gigli M; Mazzanti M; Lacalaprice F
J Cardiovasc Pharmacol; 2008 Jun; 51(6):611-5. PubMed ID: 18574390
[TBL] [Abstract][Full Text] [Related]
16. Prevention of coronary atherosclerosis by the use of combination therapy with antioxidant coenzyme Q10 and statins.
Chapidze G; Kapanadze S; Dolidze N; Bachutashvili Z; Latsabidze N
Georgian Med News; 2005 Jan; (118):20-5. PubMed ID: 15821319
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome of acute myocarditis is independent of cardiac enzyme release.
Ammann P; Naegeli B; Schuiki E; Straumann E; Frielingsdorf J; Rickli H; Bertel O
Int J Cardiol; 2003 Jun; 89(2-3):217-22. PubMed ID: 12767545
[TBL] [Abstract][Full Text] [Related]
18. Trimetazidine potentiates the effects of exercise training in patients with ischemic cardiomyopathy referred for cardiac rehabilitation.
Belardinelli R; Lacalaprice F; Faccenda E; Volpe L
Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):533-40. PubMed ID: 18797405
[TBL] [Abstract][Full Text] [Related]
19. The role of coenzyme Q10 in heart failure.
Weant KA; Smith KM
Ann Pharmacother; 2005 Sep; 39(9):1522-6. PubMed ID: 16046484
[TBL] [Abstract][Full Text] [Related]
20. [Combination treatment with coenzyme Q10 and simvastatin in patients with coronary atherosclerosis].
Chapidze G E ; Kapanadze SD; Dolidze NK; Latsabidze NE; Bakhutashvili ZV
Kardiologiia; 2006; 46(8):11-3. PubMed ID: 17047594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
